| Literature DB >> 30937296 |
Bum Soo Kim1, Young Hwii Ko2, Phil Hyun Song2, Tae-Hwan Kim1, Ki Ho Kim3, Byung Hoon Kim4.
Abstract
BACKGROUND: We hypothesized that prostatic anatomical factors may affect the progression of benign prostatic hyperplasia (BPH) and analyzed whether prostatic anatomical factors could be predictive of the risk of surgery.Entities:
Keywords: Benign prostatic hyperplasia; Risk factors; Treatment failure; Ultrasonography
Year: 2018 PMID: 30937296 PMCID: PMC6424679 DOI: 10.1016/j.prnil.2018.06.002
Source DB: PubMed Journal: Prostate Int ISSN: 2287-8882
Fig. 1Ultrasonographic measurements of prostatic urethral length (a + b + c + d), transitional zone urethral length (a + b + c), and prostatic urethral angle (e) in a midsagittal image of a transrectal ultrasound.
Comparison of patient characteristics between BPH-related surgery and nonsurgery groups.
| Parameters | Surgery (n = 37) | Nonsurgery (n = 642) | |
|---|---|---|---|
| Age (y) | 71.5 | 68.2 | 0.328 |
| PSA (ng/mL) | 5.7 | 1.1 | 0.036 |
| IPSS | 22.5 | 16.0 | <0.001 |
| QoL | 4.0 | 3.5 | 0.022 |
| Peak flow rate (mL/s) | 9.1 | 13.2 | <0.001 |
| Postvoid residual urine (mL) | 129.8 | 52.3 | <0.001 |
| Prostate volume (g) | 46.0 | 34.7 | 0.011 |
| Transitional zone volume (g) | 26.7 | 16.7 | 0.021 |
| Prostatic urethral length (cm) | 4.9 | 4.4 | 0.002 |
| Transitional zone urethral length (cm) | 3.6 | 2.9 | 0.006 |
| Presence of IPP | 8 (21.6%) | 117 (18.2%) | 0.077 |
| Length of IPP (cm) | 1.1 | 0.9 | 0.163 |
| Prostatic urethral angle (°) | 145.1 | 143.0 | 0.890 |
BPH, benign prostatic hyperplasia; IPP, intraprostatic protrusion; IPSS, international prostate symptom score; PSA, prostate-specific antigen; QoL, quality of life.
Multivariate logistic regression analysis to determine the predictive factors for BPH-related surgery.
| Parameters | Odds ratio (95% CI) | |
|---|---|---|
| PSA | 1.115 (1.031–1.532) | 0.131 |
| IPSS | 1.492 (0.351–2.937) | 0.668 |
| QoL | 1.249 (1.085–3.654) | 0.227 |
| Peak flow rate | 0.726 (0.503–1.050) | 0.089 |
| Postvoid residual urine | 0.995 (0.977–1.013) | 0.578 |
| Prostate volume | 1.132 (0.970–1.320) | 0.116 |
| Transitional zone volume | 0.843 (0.661–1.075) | 0.168 |
| Prostatic urethral length | 1.038 (1.002–1.821) | 0.037 |
| Transitional zone urethral length | 2.289 (1.536–2.459) | 0.043 |
BPH, benign prostatic hyperplasia; CI, confidence interval; IPSS, international prostate symptom score, PSA, prostate-specific antigen; QoL, quality of life.
Fig. 2Receiver operating characteristic curves for prostatic urethral length (AUC = 0.702) and transitional zone urethral length (AUC = 0.765). AUC, area under the curve; PUL, prostatic urethral length; TZUL, transitional zone urethral length.
Odds ratio and 95% confidence interval for the risk of surgery in matched cohort (1:1 pairing).
| Parameters | Surgery (n = 37) | Nonsurgery (n = 37) | Odds ratio (95% CI) | |
|---|---|---|---|---|
| Age (y) | 71.5 | 71.2 | 0.988 | 1.153 (1.102–1.311) |
| PSA (ng/mL) | 5.7 | 6.4 | 0.877 | 1.010 (0.741–1.325) |
| IPSS | 22.5 | 18.1 | 0.056 | 1.274 (0.885–1.845) |
| QoL | 4.0 | 3.5 | 0.086 | 1.288 (1.008–2.134) |
| Peak flow rate (mL/s) | 9.1 | 11.1 | 0.130 | 0.820 (0.541–1.212) |
| Postvoid residual urine (mL) | 129.8 | 80.0 | 0.085 | 1.186 (0.911–2.315) |
| Prostate volume (g) | 46.0 | 46.3 | 0.961 | 1.124 (1.101–1.322) |
| Transitional zone volume (g) | 26.7 | 23.6 | 0.526 | 1.381 (0.794–1.957) |
| Prostatic urethral length (cm) | 4.9 | 4.1 | 0.017 | 2.115 (1.745–3.241) |
| Transitional zone urethral length (cm) | 3.6 | 2.8 | 0.028 | 3.816 (2.142–6.514) |
| Presence of IPP | 8 (21.6%) | 12 (32.4%) | 0.483 | 1.215 (0.987–2.014) |
| Length of IPP (cm) | 1.1 | 0.9 | 0.464 | 0.788 (0.341–1.214) |
| Prostatic urethral angle (°) | 145.1 | 139.4 | 0.277 | 1.238 (0.956–1.874) |
BPH, benign prostatic hyperplasia; CI, confidence interval; IPP, intraprostatic protrusion; IPSS, international prostate symptom score; PSA, prostate-specific antigen; QoL, quality of life.